Observatory · observe first
Follow the allocation change
Matched S&P 500 members → sector → industry → sub-industry → company. Each step uses the same percentage points.
Historical time machine
Historical observation
20182026
1 · Sector
Weight and 12M allocation change
2 · Industry
Inside Health Care
Life Sciences Tools & Services2.30%+0.31 ppManaged Health Care2.22%+0.19 ppBiotechnology2.33%+0.06 ppHealth Care Facilities0.26%+0.03 ppHealth Care Supplies0.29%+0.02 ppHealth Care Equipment3.33%-0.02 ppHealth Care Services0.87%+0.01 ppPharmaceuticals4.84%-0.01 ppHealth Care Distributors0.29%-0.00 ppHealth Care Technology0.00%+0.00 pp
3 · Sub-industry
Inside Biotechnology
Biotechnology · weight
2.33%
Industry change · 12M
+0.06 pp
Biotechnology · contribution
+0.063 pp
Company participation
25%
of industry constituents above their 6M weight average
4 · Companies driving this sub-industry
Dec 2021 · sorted by absolute contribution to 12-month change
| Company | Country | Market cap | Universe weight | 3M contribution | 12M contribution | 12M price return | Above 6M weight average |
|---|---|---|---|---|---|---|---|
| Moderna → MRNA | United States | $103.0bn | 0.330% | -0.216 pp | +0.330 pp | +143.1% | No |
| Amgen → AMGN | United States | $126.7bn | 0.406% | -0.018 pp | -0.136 pp | +0.9% | No |
| Vertex Pharmaceuticals → VRTX | United States | $55.8bn | 0.179% | +0.014 pp | -0.070 pp | -7.1% | Yes |
| Biogen → BIIB | United States | $35.2bn | 0.113% | -0.035 pp | -0.040 pp | -2.0% | No |
| Incyte → INCY | United States | $16.2bn | 0.052% | -0.001 pp | -0.025 pp | -15.6% | No |
| Regeneron Pharmaceuticals → REGN | United States | $59.3bn | 0.190% | -0.010 pp | +0.006 pp | +30.7% | No |
| Gilead Sciences → GILD | United States | $91.1bn | 0.292% | -0.016 pp | -0.004 pp | +30.0% | No |
| AbbVie → ABBV | United States | $239.4bn | 0.767% | +0.098 pp | +0.001 pp | +32.4% | Yes |
Company contributions use weights among matched S&P 500 members and add through each level without rescaling. Companies without matched shares and prices are omitted. These observations do not establish official index weights or actual fund flows.